Versant Vantage II, L.P. - Apr 29, 2022 Form 3 Insider Report for Tempest Therapeutics, Inc. (TPST)

Role: 10%+ Owner
Signature: Versant Vantage II, L.P., By: Versant Vantage II GP, L.P. Its: General Partner, By: Versant Vantage II GP-GP, LLC Its: General Partner, By: /s/ Robin L. Praeger Its: Managing Director
Stock symbol: TPST
Transactions as of: Apr 29, 2022
Transactions value $: $0
Form type: 3
Date filed: 5/3/2022, 05:07 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TPST	Common Stock						2.12M	Apr 29, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired pursuant to a Securities Purchase Agreement dated April 26, 2022 between the Issuer, Versant Vantage II, L.P. ("Vantage II") and certain other investors. Not included on this Form 3 are an additional 997,940 shares of Common Stock held by Versant Venture Capital VI, L.P. ("VVC VI"), 1,171,094 shares of Common Stock held by Versant Venture Capital IV, L.P. ("VVC IV") and 7,377 shares of Common Stock held by Versant Side Fund IV, L.P. ("VSF IV"). Vantage II, VVC VI, VVC IV and VSF IV, along with their respective general partner entities, have filed a Form 4 on the date hereof reporting their respective holdings in a consolidated filing.
F2	These shares are held of record by Vantage II. Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP. Thomas Woiwode, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP, Vantage II GP and Thomas Woiwode disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Thomas Woiwode is a director of the Issuer and, accordingly, files separate Section 16 reports.

Content

Represents shares acquired pursuant to a Securities Purchase Agreement dated April 26, 2022 between the Issuer, Versant Vantage II, L.P. ("Vantage II") and certain other investors. Not included on this Form 3 are an additional 997,940 shares of Common Stock held by Versant Venture Capital VI, L.P. ("VVC VI"), 1,171,094 shares of Common Stock held by Versant Venture Capital IV, L.P. ("VVC IV") and 7,377 shares of Common Stock held by Versant Side Fund IV, L.P. ("VSF IV"). Vantage II, VVC VI, VVC IV and VSF IV, along with their respective general partner entities, have filed a Form 4 on the date hereof reporting their respective holdings in a consolidated filing.

These shares are held of record by Vantage II. Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP. Thomas Woiwode, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP, Vantage II GP and Thomas Woiwode disclaim beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein. Thomas Woiwode is a director of the Issuer and, accordingly, files separate Section 16 reports.